Can

Diagnosis High grade serous ovarian cancer Next generation sequencing P53 immunohistochemistry TP53 variant negative

Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
May 2021
Historique:
received: 06 11 2020
revised: 31 01 2021
accepted: 07 02 2021
entrez: 15 3 2021
pubmed: 16 3 2021
medline: 16 3 2021
Statut: epublish

Résumé

Identifiants

pubmed: 33718561
doi: 10.1016/j.gore.2021.100729
pii: S2352-5789(21)00034-5
pmc: PMC7910505
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100729

Informations de copyright

© 2021 Published by Elsevier Inc.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Clin Cancer Res. 2020 Sep 15;26(18):4767-4776
pubmed: 32611648
PLoS Med. 2016 Dec 20;13(12):e1002198
pubmed: 27997533
Am J Surg Pathol. 2006 Feb;30(2):230-6
pubmed: 16434898
J Pathol Clin Res. 2016 Jul 13;2(4):247-258
pubmed: 27840695
Mod Pathol. 2021 Feb;34(2):490-501
pubmed: 32801341
Clin Cancer Res. 2018 Dec 15;24(24):6168-6174
pubmed: 30108107
Nat Commun. 2019 Nov 26;10(1):5367
pubmed: 31772167
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
J Pathol. 2019 Nov;249(3):274-285
pubmed: 31322742
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Carcinogenesis. 2005 Oct;26(10):1651-6
pubmed: 15917310
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546879
Front Oncol. 2020 Jul 16;10:1103
pubmed: 32766142
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Transl Cancer Res. 2016 Dec;5(6):650-663
pubmed: 30613473
J Clin Oncol. 2005 Jan 1;23(1):154-64
pubmed: 15625370
Int J Mol Sci. 2015 Jul 09;16(7):15531-45
pubmed: 26184161

Auteurs

Lawrence Kasherman (L)

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.

Swati Garg (S)

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.

Nairi Tchrakian (N)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Blaise Clarke (B)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Katherine Karakasis (K)

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.

Raymond H Kim (RH)

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
Familial Cancer Clinic, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.

Tracy L Stockley (TL)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto ON.

Neesha Dhani (N)

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.

Amit M Oza (AM)

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.

Stephanie Lheureux (S)

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.

Classifications MeSH